Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects on ultrafiltration in peritoneal dialysis patients with chronic heart failure
jRCTs051230081Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin in chronic heart failure (CHF) and end-stage kidney disease (ESKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change in ultrafiltration volume with dextrose peritoneal dialysis solution. Started Dec 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic heart failure (CHF)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCTs051230081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230081.